AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 212 min read$ALKS

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.

Original reporting
benzinga.com
Published Sep 21, 2026, 5:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 5:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS) — source image
Source · benzinga.com
Decision brief

The 30-second read

$ALKSBullishMed
01

Why it matters

The data suggest a novel mechanism could address unmet needs in ADHD, potentially expanding Alkermes' pipeline value.

02

Market read

First positive Phase 1 data for a new ADHD therapy; modest stock impact expected.

03

What to watch

Regulatory timeline, reimbursement landscape, and potential need for larger trials could delay commercialization.

Relevance 8/10Novelty 8/10Timing: Monday release

Background

Alkermes plc (NASDAQ:ALKS) disclosed topline Phase 1 results for its orexin 2 receptor agonist ALKS 7290 aimed at adult ADHD.

Company-level read

Ticker impact

$ALKSBullishMedium confidence
Context

Alkermes released first Phase 1 data for ALKS 7290 showing dose‑dependent ADHD symptom improvement.

Expected impact

Potential modest upside as investors price in a novel mechanism; risk remains high until Phase 2.

Evidence & confidence

Phase 1 results are encouraging but early; market typically reacts positively to novel biotech data, though size of move is limited.

Market effects

Sector

Adds momentum to the ADHD therapeutic space and orexin‑targeted drug pipeline.

Regional

US biotech sector may see slight uplift; European investors with exposure to Alkermes could react similarly.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Early data may be overhyped; Phase 1 safety does not guarantee Phase 2 success, and competition is intense.

Key entities

  • company
    Alkermes plc

    Biopharma company developing ALKS 7290 for ADHD.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 21
$ALKSMedAI 8/10

What This Biotech Learned From Narcolepsy And Took To ADHD

Alkermes (ALKS) stock rose Monday after its orexin-modulating drug, ALKS7290, showed initial positive results in adults with ADHD. The drug targets orexin, a brain chemical linked to wakefulness, previously studied for insomnia and narcolepsy. This marks the first potential breakthrough in ADHD treatment using this approach.

investors.com1 min
SEP 21
$ALKSHighAI 8/10

Why is Alkermes stock surging today?

Alkermes stock rose 8.4% premarket after positive Phase 1b study results for ALKS 7290, an ADHD treatment. The trial showed significant symptom reduction in adults. The company highlights this as the first orexin 2 receptor agonist to demonstrate such improvements. Analysts have recently supported Alkermes' orexin platform, which targets multiple neurological indications.

investing.com2 min
SEP 21
$ALKSMedAI 8/10

Alkermes plc. (ALKS): Regulation FD Disclosure

Alkermes plc. (ALKS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD

SEC EDGAR 8-K2 min
AUG 28
$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

sleepreviewmag.com2 min
AUG 27
$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

simplywall.st2 min